GlassScriptPhysician profile
Beinaz Menagi
NPI 1104918861
$279.39
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $45.99 · 2022: $14.53.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.12 | 2019 | |
| Novo Nordisk INC | $38.49 | 2019 | |
| Astellas Pharma US INC | $34.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.92 | 2019 | |
| Pfizer INC. | $27.45 | 2020-2022 | |
| Sanofi Pasteur INC. | $20.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.79 | 2020 | |
| Amgen INC. | $13.53 | 2019 | |
| Amarin Pharma, INC. | $13.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beinaz Menagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.